Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
French National Agency for Research on AIDS and Viral Hepatitis |
---|---|
Information provided by: | French National Agency for Research on AIDS and Viral Hepatitis |
ClinicalTrials.gov Identifier: | NCT00657397 |
The rapid scale up of opioid substitution treatment (OST) for drug users mainly achieved through the possibility of prescribing buprenorphine in primary care has been successful in reducing HIV prevalence among drug users but still inadequate for reducing the spread of HCV. To date, methadone in France can only be initialised in drug centres but GPs can prescribe methadone after stabilisation of dosages.
This study was born as an answer to a request from the French Minister of Health that supports the initialisation of methadone in primary care in order to improve coverage by OST (now 70%) in Intravenous drug users.
Condition | Intervention | Phase |
---|---|---|
Hepatitis C Substance Dependence Methadone |
Drug: Methadone |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Initialization of Methadone in Primary Care; a Randomized Intervention Research for Preventing HCV Transmission Practices. ANRS Methaville |
Estimated Enrollment: | 300 |
Study Start Date: | September 2008 |
Estimated Study Completion Date: | September 2010 |
Estimated Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental
Methadone prescribed by general physician
|
Drug: Methadone |
B: Active Comparator
Methadone prescribed in centres for the treatment of drugs dependence (CSST)
|
Drug: Methadone |
The rapid scale up of opioid substitution treatment (OST) for drug users mainly achieved through the possibility of prescribing buprenorphine in primary care has been successful in reducing HIV prevalence among drug users but still inadequate for reducing the spread of HCV. To date, methadone in France can only be initialised in drug centres but GPs can prescribe methadone after stabilisation of dosages.
This study was born as an answer to a request from the French Minister of Health that supports the initialisation of methadone in primary care in order to improve coverage by OST (now 70%) in Intravenous drug users.
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
France | |
CSST Le trait d'union | |
Boulogne, France, 92100 |
Principal Investigator: | Alain Morel, MD | CSST Le trait d'union, 154 rue du vieux pont de Sèvres, 92100 Boulogne, France |
Study Director: | Patrizia Carrieri, PHD | ORS PACA - INSERM-IRD UMR912, 23, rue Stanislas Torrents, 13006 Marseille |
Responsible Party: | ANRS ( Christelle Paul regulatory affairs ) |
Study ID Numbers: | ANRS Methaville |
Study First Received: | April 8, 2008 |
Last Updated: | June 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00657397 |
Health Authority: | France: Direction Générale de la Santé |
Methadone Substance Dependence |
Liver Diseases Hepatitis, Viral, Human Disorders of Environmental Origin Hepatitis Virus Diseases Naphazoline Methadone Oxymetazoline |
Digestive System Diseases Guaifenesin Mental Disorders Phenylephrine Substance-Related Disorders Phenylpropanolamine Hepatitis C |
Respiratory System Agents RNA Virus Infections Flaviviridae Infections Physiological Effects of Drugs Central Nervous System Depressants Narcotics Pharmacologic Actions |
Sensory System Agents Therapeutic Uses Analgesics Peripheral Nervous System Agents Antitussive Agents Central Nervous System Agents Analgesics, Opioid |